

# PROVINCIAL FUNDING SUMMARY

Brentuximab (Adcetris) for Hodgkin Lymphoma Resubmission (pCODR 10145)

pERC Recommendation: Does not recommend  
 For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: March 22, 2019

This information is current as of July 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Jun 1, 2014	If transplant ineligible due to age or co-morbid conditions, have relapsed after standard ABVD or equivalent. - NOTE: A BCCA “Compassionate Access Program” request with appropriate clinical information for each patient must be approved prior to treatment.
AB	Under provincial consideration		
SK	Not funded		
MB	Under provincial consideration		
ON	Under provincial consideration		
NS	Under provincial consideration		
NB	Not funded		
NL	Not funded		
PEI	Not funded		

*Under provincial consideration* means that the province is reviewing pCODR’s recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.